Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia.
about
Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patientsNystatin prophylaxis and treatment in severely immunodepressed patientsAmphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropeniaRoutine versus selective antifungal administration for control of fungal infections in patients with cancerNystatin prophylaxis and treatment in severely immunodepressed patients.Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients.Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia.Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model.Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.Routine versus selective antifungal administration for control of fungal infections in patients with cancer.Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B.Towards a targeted, risk-based, antifungal strategy in neutropenic patients.Prophylactic antifungal therapy in the intensive care unit.A strategy for managing fungal infections in haematopoietic stem cell transplantation.Impaired gut function as risk factor for invasive candidiasis in neutropenic patients.Preventing microbial translocation in haematological malignancy.Oesophageal candidiasis in elderly patients: risk factors, prevention and management.Current and future therapeutic options in the management of invasive aspergillosis.Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic stem cell transplantation.Pre-emptive treatment of fungal infection based on plasma β-D-glucan levels after gastric surgery for gastric cancer in elderly patients.Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy.Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin.Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer.Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice.Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.Need for Alternative Trial Designs and Evaluation Strategies for Therapeutic Studies of Invasive Mycoses
P2860
Q24193785-154417F3-2047-4BB1-A732-0D6BCCFD566BQ24193801-8F8504D9-DFDA-496D-9FD2-A496092A32FFQ24193811-0EBB4467-4E8D-4237-813D-63171A433754Q24193817-8975A006-71FE-4558-BD35-6E21D01312BBQ30868327-B17BCBDB-2F42-4BDD-8EE6-B13DB0E37784Q30887333-EB837342-0B04-43DA-B94C-31A050D45C96Q30887348-F6A615FB-3A46-45CA-B151-8D793C5968A5Q31120454-4D7EB892-C6A3-471A-BC0B-05E108C00D19Q31372000-DBE056C2-1BE0-4163-AC4D-0C5095D347AAQ33608832-E6B2A3E3-B9E4-4ECA-BB81-B7F0A7B340EBQ33909375-856799B2-5954-423B-B7B0-BC31C494D3EAQ33980029-739EA8D2-D1D2-4F40-AE9D-F3A2D8A5F29AQ34022479-A97D336A-8BD4-421F-9EC6-F798FE800FD9Q34205622-4B8B9548-E10F-481A-BD58-B79BE6327FC8Q34294925-4B94F7A8-45E3-4224-B9D8-38C3D007DB2FQ34612183-0D60A7A6-2592-4893-B136-6C7E0210091FQ35746604-6E03A864-1E59-4F33-BD2A-97C3E8663ABEQ37079085-7BB8F3EC-568E-43F5-8919-4B0942480A4FQ37079099-CB1CA3B7-5B74-4249-AD45-91B499FD7BD8Q40153913-B1A5A514-6075-406B-8A88-0C9BF4F4D55FQ40251593-A5D4F606-6DC3-49B6-BD10-F40D14861218Q40487519-E3E1B615-C609-4349-865B-43A019DF98A8Q40489288-67988313-138B-4195-9624-2277E97E3351Q40595108-30B5BB40-2130-4188-82D8-88EA7FC57F16Q44062340-DD18F772-F452-40C1-849D-81C70AF58539Q44750606-D6FF6921-3F06-4968-8E43-3DA1F5049A48Q44878439-9BB2260C-2EDE-49BA-9F44-4EF7B5CCD45AQ45168346-76C5A449-468F-4F44-81FD-02DC5E004529Q54034991-51602C44-A863-4112-9785-FC3533613B4DQ56837353-947AE1F4-AE90-4AE9-86EE-DC13CF5B2723
P2860
Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Meta-analysis of prophylactic ...... er complicated by neutropenia.
@ast
Meta-analysis of prophylactic ...... er complicated by neutropenia.
@en
type
label
Meta-analysis of prophylactic ...... er complicated by neutropenia.
@ast
Meta-analysis of prophylactic ...... er complicated by neutropenia.
@en
prefLabel
Meta-analysis of prophylactic ...... er complicated by neutropenia.
@ast
Meta-analysis of prophylactic ...... er complicated by neutropenia.
@en
P1433
P1476
Meta-analysis of prophylactic ...... er complicated by neutropenia.
@en
P2093
Johansen HK
P304
P356
10.1136/BMJ.314.7089.1238
P407
P577
1997-04-01T00:00:00Z